Phase 1 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with mild to moderate stage Alzheimer's dementia
- People who have specific biological markers in their body that confirm Alzheimer's disease, as defined by internationally recognised diagnostic guidelines (the NIA-AA 2024 criteria)
- People who are able to understand and agree to take part in the trial on their own behalf
Who may not be able to join:
- People for whom a colonoscopy (a camera examination of the large bowel) would be medically unsafe or not recommended
- People for whom an MRI scan would be medically unsafe or not recommended (for example, due to certain metal implants)
- People whose life expectancy is estimated to be less than one year
- People who score 7 or higher on the Clinical Frailty Scale, which indicates severe frailty or worse (confirm with trial site)
- People with a history of seizures or epilepsy
- People with a history of a brain tumour or bleeding inside the skull
- People with a major psychiatric condition such as schizophrenia, bipolar disorder, or severe depression
- People with a history of alcohol or drug misuse
- People with serious heart disease that is not well controlled
- People who have or have had cancer
- People currently taking blood-thinning medications such as warfarin or dual-acting oral anticoagulants
- People who are pregnant or planning to become pregnant
- People found to have large bowel polyps greater than 1 cm, tumours, or signs of active bowel inflammation on colonoscopy
- People who have had part or all of their large bowel surgically removed
- People with inflammatory bowel disease (such as Crohn's disease or ulcerative colitis)
- People whose immune system is weakened or suppressed
- People currently receiving biological or antibody-based treatments (confirm with trial site for specific medicines)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mona Dixon Gundersen, MBChB, PhD, University Hospital of North Norway, Tromsø
Phone: +47 77798916
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of treatment-related adverse events and serious adverse events. [Safety]; Rate of participant recruitment [Feasibility]; Number participants that complete colonoscopy [Feasibility]; Time used per intervention [Feasibility]; Number that meet study eligibility [Feasibility]; Number that complete study [Feasibility]; Engraftment of faecal microbiota transplantation (FMT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.